David M O'Malley MD

Gynecologic Oncology

Professor of Obstetrics & Gynecology The Ohio State University and James CCC; Director, Clinical Research Gynecologic Oncology; ORIEN Physician Liaison for OSUCCC-James

Join to View Full Profile

3651 Ridge Mill DrOSU Dept Obstetrics/Gynecology, M210 Starling Loving HallHilliard, OH 43026
Phone+1 614-293-3873
Fax+1 614-293-3078

Education & Training

Yale-New Haven Medical CenterFellowship, Gynecologic Oncology, 2002 - 2005
The MetroHealth System/Case Western Reserve UniversityResidency, Obstetrics and Gynecology, 1998 - 2002
Cleveland Clinic FoundationResidency, Obstetrics and Gynecology, 1998 - 2002
Wayne State University School of MedicineClass of 1998
University of Notre DameBA, Pre-Med, 1989 - 1992

Certifications & Licensure

OH State Medical License 2005 - 2028
CT State Medical License 2002 - 2006
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma Start of enrollment: 2007 Aug 01
COMPLETED
PHASE2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
ACTIVE_NOT_RECRUITING
PHASE3

Publications & Presentations

PubMed

13 citations
Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data
Rebecca C. Arend, David M. O'Malley, Susana Banerjee, Kimmie K. McLaurin, Richard Davidson
Advances in Therapy. 2021-11-02
49 citations
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label...
Stephanie Gaillard, Ana Oaknin, Isabelle Ray-Coquard, Ignace Vergote, Giovanni Scambia
Gynecologic Oncology. 2021-11-01
27 citations
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Elizabeth M. Swisher, Rebecca Kristeleit, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard
Gynecologic Oncology. 2021-09-30

Journal Articles

Phase Ib Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Pl...
David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lainie P Martin, Kathleen N Moore, Gynecologic Oncology

Lectures

Mirvetuximab soravtansine, a folate receptor alpha (FRÎ±)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resi...
2019 ASCO Annual Meeting - 6/1/2019
Mirvetuximab soravtansine, a folate receptor alpha (FR±)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resis...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

David O'Malley, MD, on Dual Immunotherapy for Advanced Cervical CancerMarch 9th, 2022
ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with AvastinMay 15th, 2019
ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with AvastinMay 16th, 2018